Our perspective on AL/ML in the life sciences industry.
The stakes in clinical research have never been higher. While breakthrough treatments show tremendous promise, the reality is sobering: bringing a single drug to market
Clinical trials are under more pressure than ever to move fast; yet documentation remains a stubborn bottleneck. According to the NIH, documentation delays contribute to
Healthcare data generates an astonishing 30% of the world’s total data, yet 80% of it remains unstructured- trapped in clinical notes, research papers, and disparate
The European Union recently released its comprehensive AI Act, marking a watershed moment as the world’s first-ever legal regulatory framework specifically designed to govern artificial
Clinical trials have long been a critical, but complex and costly part of drug development. However, with the rise of Artificial Intelligence (AI) & Machine
Artificial Intelligence (AI) and Machine Learning (ML) have become key players in reshaping how we develop drugs, but with this potential comes the critical need
In our previous blog, we took an in-depth look at AI hallucinations, including what they are, why they matter, and how they can be measured.
Generative AI (GenAI) holds enormous potential across a wide range of use cases in the clinical development space, but its tendency to hallucinate must be
At Saama, our mission is to empower life sciences companies with advanced AI-driven solutions that improve human health. We believe that by enabling faster, more
